CompletedInterventionalPhase 1Updated Mar 14, 2018
Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or... | NCT01494753 | Trialant
CompletedInterventionalPhase 2Updated Feb 7, 2024
Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension
ClinicalTrials.gov ID
NCT01494753
Lead Sponsor
Laboratoires TheaINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
30Actual
Last Update Posted
Feb 7, 2024Actual
Start Date
Jun 2008
Primary Completion Date
Dec 2008Actual
Completion Date
Dec 2008Actual
Brief Summary
The purpose of this study is to assess the pharmacokinetics, efficacy and safety of T2345 versus an active comparator.
Primary Open Angle Glaucoma
T2345
Prostaglandin
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Untreated bilateral newly diagnosed patients with primary open angle glaucoma
Exclusion Criteria:
Any ocular hypertension other than chronic open angle glaucoma